Last reviewed · How we verify

Fabhalta — Competitive Intelligence Brief

Fabhalta (IPTACOPAN) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Factor B Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Fabhalta (IPTACOPAN) — Novartis. Iptacopan binds to Factor B, regulating C3 cleavage and downstream effects in the alternative complement pathway, controlling IVH and EVH in PNH and inhibiting local activation in IgAN and C3G.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fabhalta TARGET IPTACOPAN Novartis marketed Factor B 2023-01-01
Nulibry FOSDENOPTERIN Sentynl Theraps Inc marketed Cyclic Pyranopterin Monophosphate Molybdenum cofactor biosynthesis protein 1 2021-01-01
Eylea Eylea Texas Retina Associates marketed Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B
Juvista (Avotermin) Juvista (Avotermin) Renovo phase 3 Recombinant growth factor TGF-β3 (Transforming Growth Factor Beta-3)
TG-C TG-C Kolon TissueGene, Inc. phase 3 Gene therapy TGF-β3 (Transforming Growth Factor Beta 3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fabhalta — Competitive Intelligence Brief. https://druglandscape.com/ci/iptacopan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: